Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus.

A 26-year-old woman with lymphangioleiomyomatosis (LAM) was hospitalized for the surgical excision of a giant abdominal tumor of right kidney origin. The pathological diagnosis of the tumor was conventional angiomyolipoma (AML). After 8 months, 2 liver tumors appeared and grew rapidly. The tumors were resected, and the pathological finding of these tumors was epithelioid AML. Thereafter, metastatic multiple lung tumors appeared, and there was local recurrence of the liver tumors. Sirolimus, an mTOR protein inhibitor, was used to treat epithelioid AML. However, the drug did not inhibit the rapid growth of the tumor at all. This finding suggests that sirolimus might not be effective against epithelioid AML, and in such cases, complete surgical resection should be the treatment of choice.

[1]  P. Crino,et al.  The tuberous sclerosis complex. , 2006, The New England journal of medicine.

[2]  Erick M Remer,et al.  Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. , 2008, The Journal of urology.

[3]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[4]  F. Elmslie,et al.  Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[5]  A. Folpe,et al.  Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. , 2007, Human pathology.

[6]  W. Kim,et al.  Protein expression and mutational analysis of epidermal growth factor receptor in renal angiomyolipomas , 2007, Pathology international.

[7]  H. L. Kim,et al.  Clinical presentation of epithelioid angiomyolipoma , 2007, International journal of urology : official journal of the Japanese Urological Association.

[8]  M. Kaplan,et al.  Renal angiomyolipoma with malignant transformation, simultaneous occurrence with malignity and other complex clinical situations , 2007, International Urology and Nephrology.

[9]  D. Brancaccio,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Isolation and Growth of Smooth Muscle-Like Cells Derived from Tuberous Sclerosis Complex-2 Human Renal Angiomyolipoma Epidermal Growth Factor Is the Required Growth Factor , 2005 .

[10]  C. Aul,et al.  Antiangiogenetische Therapie eines Nieren-Angiomyolipoms bei einer schwerstbehinderten Patientin mit Multipler Sklerose , 2005 .

[11]  C. Aul,et al.  [Anti-angiogenic therapy of a renal angiomyolipoma in a seriously disabled patient suffering from multiple sclerosis]. , 2005, Aktuelle Urologie.

[12]  E. Henske,et al.  Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[13]  M. Benghanem,et al.  Renal manifestations of tuberous sclerosis complex. , 2003, Annales de medecine interne.

[14]  Tadashi Suzuki,et al.  Malignant transformation of renal angiomyolipoma , 2003, International journal of urology : official journal of the Japanese Urological Association.

[15]  Hongbing Zhang,et al.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma , 2003, The Lancet.

[16]  J. Boelaert,et al.  Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Tsuyoshi Saito,et al.  Malignant Transformation of Renal Angiomyolipoma: A Case Report , 2002, The American journal of surgical pathology.

[18]  A. Gown,et al.  Renal angiomyolipoma: further immunophenotypic characterization of an expanding morphologic spectrum. , 2001, Archives of pathology & laboratory medicine.

[19]  G. Zamboni,et al.  Renal angiomyolipoma with epithelioid sarcomatous transformation and metastases: demonstration of the same genetic defects in the primary and metastatic lesions. , 2000, The American journal of surgical pathology.

[20]  E. Henske,et al.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.